当前位置: X-MOL 学术Clin. Exp. Allergy › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Clinical & Experimental Allergy ( IF 6.1 ) Pub Date : 2021-05-26 , DOI: 10.1111/cea.13954
Jennifer D Hamilton 1 , Sivan Harel 1 , Brian N Swanson 2 , William Brian 2 , Zhen Chen 1 , Megan S Rice 3 , Nikhil Amin 1 , Marius Ardeleanu 1 , Allen Radin 1 , Brad Shumel 1 , Marcella Ruddy 1 , Naimish Patel 2 , Gianluca Pirozzi 2 , Leda Mannent 4 , Neil M H Graham 1
Affiliation  

Type 2 inflammation is common in numerous atopic/allergic diseases and can be identified by elevated biomarker levels. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation.

中文翻译:

Dupilumab 抑制多种特应性、过敏性疾病的 2 型炎症生物标志物

2 型炎症在许多特应性/过敏性疾病中很常见,并且可以通过升高的生物标志物水平来识别。Dupilumab 是一种全人源单克隆抗体,可阻断白细胞介素 4 和白细胞介素 13 的共享受体成分,它们是 2 型炎症的关键和中心驱动因素。
更新日期:2021-06-28
down
wechat
bug